Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats

Brain Research

Volumn 735, Issue 2, 1996, Pages 349-353

  Fornai, Francesco ^a,b   Torracca, Maria Tilde ^a   Bassi, Lucia ^b   D'Errigo, Daniela Anna ^a   Scalori, Vera ^a   Corsini, Giovanni U ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Associazione Anni Verdi   (Italy)

Author keywords

Dopamine; DSP 4; Methamphetamine; Neurotoxic threshold; Nigrostriatal pathway; Norepinephrine

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; DOPAMINE; METHAMPHETAMINE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; RAT;

EID: 0030574095     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00891-8     Document Type: Article

References (21)

1. [1] Albers, D.S, and Sonsalla, P.K., Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents, J. Pharmacol. Exp. Ther., 275 (1995) 1104-1114.
2. [2] Alvord, E.C. Jr. and Forno, L.S., Pathology. In W.C Koller (Ed.), Handbook of Parkinson's Disease, 2nd edn., Marcel Dekker, New York. 1992, pp. 255-284.
3. [3] Bing, G., Zhang, Y., Watanabe, Y., McEwen, B.S. and Stone, E.A., Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra, Brain Res., 668 (1994) 261-265.
4. [4] Bowyer, J.F., Tank, A.W., Newport, G.D., Slikker, W., Ali, S.F. and Holson, R.R., The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum, J. Pharmacol. Exp. Ther., 260 (1992) 817-824.
5. [5] Corsini, G.U., Vaglini, F., Zuddas, A., Fornai F., Saginario A., Scalori V., Excitatory amino acids, MPTP toxicity and dopaminergic nerve cell death in Parkinson's disease. In Y. Agid (Ed.), Current Trends in the Treatment of Parkinson 's Disease, John Libbey and Co., London, 1992, pp. 5-17.
6. [6] Follesa, P. and Mocchetti, I., Regulation of basic fibroblast growth factor and nerve growth factor mRNA by beta-adrenergic receptor activation and adrenal steroids in rat central nervous system, Mol. Pharmacol., 43 (1993) 132-138.
7. [7] Fornai, F., Bassi, L., Torracca, M.T., Scalori, V. and Corsini, G.U., Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice, Eur. J. Pharmacol., 283 (1995) 99-102.
8. [8] German, D.C., Manaye, K.F., White, C.L., Woodward, D.J., McIntire, D.D., Smith, W.K., Kalaria, R.N. and Mann, D., Disease-specific patterns of locus coeruleus cell loss, Ann. Neurol., 3, (1992) 667-676.
9. [9] Greenfield, J.G. and Bosanquet, F.D., The brainstem lesions in parkinsonism, J. Neurol. Neurosurg. Psychiatry, 16 (1953) 213-226.
10. [10] Grzanna, R., Berger, U., Fritschy, J. and Geffard, M., Acute actions of DSP-4 on central norepinephrine axons: biochemical and immunohistochemical evidence for differential effects., J. Histochem. Cytochem., 37 (1989) 1435-1442.
11. [11] Hornykiewicz, O. and Kish, S.J., Biochemical pathophysiology of Parkinson's disease, Adv. Neurol., 45 (1986) 19-34.
12. [12] Johannessen, J.N., Chiueh, C.C., Burns, R.S. and Markey, S.P., Differences in the metabolism of MPTP in rodent and primate parallel differences in sensitivity to its neurotoxic effects, Life Sci., 36 (1985) 219-224.
13. [13] Jonsson, G., Hallman H., Ponzio F. and Ross S., DSP-4 (N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine) a useful denervation tool for central and peripheral noradrenaline neurons, Eur. J. Pharmacol., 72 (1981) 173-188.
14. [14] Leroux-Nicollet, I., Panissot, G. and Costentin, J., Involvement of norepinephrine neurons in the hypothermia induced by intracerebroventricular administration of 6-hydroxydopamine in mice, evidenced by antidepressants, J. Neurol Transm., 74 (1988) 17-27.
15. [15] Marien, M., Briley, M. and Colpaert, F., Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice, Eur. J. Pharmacol., 236 (1993) 487-489.
16. [16] Mavridis, M., Degryse, A.-D., Lategan, A.J., Marien, M.R. and Colpaert, P.C., Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease, Neuroscience, 41 (1991) 507-523.
17. [17] Minor, B.G., Danysz, W., Jonsson, G., Mohammed, A.K., Post, C. and Archer, T., Adaptive changes in alpha-2 adrenoceptor mediated responses: analgesia, hypothermia and hypoactivity, Pharmacol. Toxicol., 65 (1989) 148-151.
18. [18] Otto, D. and Unsicker, K., Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice, J. Neurosci., 10 (1990) 1912-1921.
19. [19] Ricaurte, G.A., Schuster, C.R. and Seiden, L.S., Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study, Brain Res., 193 (1980) 153-163.
20. [20] Ross, S.B., Long-term effects of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart, Br. J. Pharmacol., 58 (1976) 521-527.
21. [21] Saper, C.B., Sorrentino, D.M., German, D.C. and Lacalle, S.L., Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease, Ann. Neurol., 29 (1991) 577-584.